<DOC>
	<DOCNO>NCT00004604</DOCNO>
	<brief_summary>RATIONALE : Biological therapy use different way stimulate immune system stop cancer cell grow . PURPOSE : Phase I trial study effectiveness biological therapy treat patient metastatic cancer respond previous treatment .</brief_summary>
	<brief_title>Biological Therapy Treating Patients With Metastatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety dose limit toxicity intravenous vaccine autologous , culture , dendritic cell pulse carcinoembryonic antigen ( CEA ) RNA patient metastatic adenocarcinoma express CEA . II . Assess cellular immune response CEA protein . III . Assess clinical biochemical response treatment duration response . OUTLINE : This three tiered , open label , uncontrolled , dose escalation study . The first 3 patient receive low dose intravenous carcinoembryonic antigen ( CEA ) RNA-pulsed autologous dendritic cell ( DC ) week 0 , 1 , 2 , 3 . Patients evaluate dose limit toxicity ( DLT ) , immune response , antitumor response least 1 week dose escalation may proceed . If DLT first three , next 3 patient treated medium dose CEA RNA-pulsed autologous DC 0 , 1 , 2 , 3 week . Finally , DLT see medium dose , final 6 patient receive intravenous infusion high dose CEA RNA-pulsed autologous DC week 0 , 1 , 2 , 3 . If 1-2 patient ( ) experience DLT either low medium dose level , 3 patient enter dose . If DLT occur , dose escalation continue . As soon 3 toxic event occur 3-6 patient one dose level , accrual level cease . The MTD define dose level immediately 3 6 patient develop DLT . PROJECTED ACCRUAL : A minimum 3 maximum 18 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Bile Duct Neoplasms</mesh_term>
	<mesh_term>Testicular Neoplasms</mesh_term>
	<mesh_term>Gallbladder Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic adenocarcinoma express carcinoembryonic antigen ( CEA ) fail conventional therapy Measurable evaluable disease May include elevate CEA level No previously irradiate known new CNS metastases PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : Greater 6 month Hematopoietic : WBC least 3,000/mm3 Absolute lymphocyte count least 1,000/mm3 Hemoglobin least 9 g/dL Platelet count least 100,000/mm3 PT less 1.25 time normal limit PTT le 1.66 time normal limit Fibrinogen great 0.75 time normal limit Hepatic : Bilirubin le 2.0 mg/dL Renal : Creatinine le 2.5 mg/dL Cardiovascular : No NYHA class III IV Pulmonary : FEV1 great 70 % predict FVC great 70 % predict DLCO great 70 % predict No asthma chronic obstructive pulmonary disease Other : No active chronic infection ( include urinary tract infection ) No viral hepatitis HIV negative No concurrent second malignancy nonmelanoma skin cancer control superficial bladder cancer No hepatic disease No history autoimmune disease inflammatory bowel disease , systemic lupus erythematous , ankylose spondylitis , scleroderma , multiple sclerosis PRIOR CONCURRENT THERAPY : Must recover acute toxic effect Biologic therapy : No concurrent biologic therapy At least 6 week since biologic therapy No concurrent immunotherapy No 1 prior biologic regimen Chemotherapy : No concurrent chemotherapy At least 6 week since chemotherapy No 1 prior chemotherapy regimen Endocrine therapy : At least 6 week since steroid therapy Radiotherapy : No concurrent radiotherapy At least 12 week since therapy include Sr 89 At least 6 week since radiotherapy No prior cranial radiotherapy Surgery : Not specify Other : No concurrent immunosuppressives azathioprine cyclosporine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>inflammatory breast cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>extensive stage small cell lung cancer</keyword>
	<keyword>recurrent small cell lung cancer</keyword>
	<keyword>unresectable gallbladder cancer</keyword>
	<keyword>recurrent gallbladder cancer</keyword>
	<keyword>unresectable extrahepatic bile duct cancer</keyword>
	<keyword>recurrent extrahepatic bile duct cancer</keyword>
	<keyword>stage III malignant testicular germ cell tumor</keyword>
	<keyword>recurrent malignant testicular germ cell tumor</keyword>
	<keyword>thyroid gland medullary carcinoma</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>stage IV salivary gland cancer</keyword>
	<keyword>recurrent salivary gland cancer</keyword>
	<keyword>Paget disease breast invasive ductal carcinoma</keyword>
	<keyword>adult primary hepatocellular carcinoma</keyword>
	<keyword>testicular yolk sac tumor</keyword>
	<keyword>lung metastasis</keyword>
	<keyword>liver metastasis</keyword>
	<keyword>cholangiocarcinoma gallbladder</keyword>
	<keyword>cholangiocarcinoma extrahepatic bile duct</keyword>
	<keyword>male breast cancer</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>